{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:47:09Z","timestamp":1775573229289,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clinthera.2023.12.002","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T08:04:13Z","timestamp":1704701053000},"page":"96-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis"],"prefix":"10.1016","volume":"46","author":[{"given":"Gregory S.","family":"Sawicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-7559","authenticated-orcid":false,"given":"Wolfgang W.","family":"Wicha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara S.","family":"Hiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C.","family":"Close","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Gelone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine J.","family":"Guico-Pabia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.12.002_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0003","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1513\/AnnalsATS.201405-203AS","article-title":"Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi","volume":"11","author":"Chmiel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0004","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jpeds.2005.10.019","article-title":"Cystic fibrosis pulmonary exacerbations","volume":"148","author":"Ferkol","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0092-8674(92)90155-6","article-title":"Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR)","volume":"68","author":"Bear","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0006","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1172\/JCI115582","article-title":"Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia","volume":"89","author":"Denning","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0007","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0009","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcf.2019.08.006","article-title":"Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis\u2014data from the European Cystic Fibrosis Society patient registry","volume":"19","author":"Hatziagorou","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0010","unstructured":"Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2021 annual data report. https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf. Accessed January 24, 2023."},{"key":"10.1016\/j.clinthera.2023.12.002_bib0011","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.201011-1892OC","article-title":"Infection, inflammation, and lung function decline in infants with cystic fibrosis","volume":"184","author":"Pillarisetti","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0012","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2008.08.001","article-title":"Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis","volume":"154","author":"Sagel","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0013","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ppul.23217","article-title":"Risk factors for lung function decline in a large cohort of young cystic fibrosis patients","volume":"50","author":"Cogen","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0014","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200802-327OC","article-title":"Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis","volume":"178","author":"Dasenbrook","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0016","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial","volume":"69","author":"File","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0017","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0018","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jgar.2021.10.021","article-title":"Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin","volume":"29","author":"Paukner","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0019","series-title":"Lefamulin","year":"2021"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0020","unstructured":"European Medicines Agency. Xenleta. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xenleta. Accessed March 14, 2023."},{"key":"10.1016\/j.clinthera.2023.12.002_bib0021","doi-asserted-by":"crossref","first-page":"39004","DOI":"10.1038\/srep39004","article-title":"A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism","volume":"6","author":"Eyal","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0022","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1128\/AAC.00358-13","article-title":"Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY Antimicrobial Surveillance Program in 2010","volume":"57","author":"Paukner","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02161-18","article-title":"Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY antimicrobial surveillance program (2015-2016)","volume":"63","author":"Paukner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0024","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/AAC.02106-12","article-title":"Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections","volume":"57","author":"Prince","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0025","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/AAC.00627-16","article-title":"In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States","volume":"60","author":"Mendes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0026","doi-asserted-by":"crossref","first-page":"e02008","DOI":"10.1128\/AAC.02008-16","article-title":"In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China","volume":"61","author":"Waites","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02380-17","article-title":"In vitro activity of lefamulin against sexually transmitted bacterial pathogens","volume":"62","author":"Paukner","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0028","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jpm11060458","article-title":"CFTR modulators: does one dose fit all?","volume":"11","author":"van der Meer","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0029","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","article-title":"The pharmacokinetics of antibiotics in cystic fibrosis","volume":"17","author":"Akkerman-Nijland","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0030","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1111\/bcp.15434","article-title":"Antibiotic hypersensitivity in cystic fibrosis - low frequency of anaphylaxis over 16 000 courses","volume":"88","author":"Kowalik","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 3","key":"10.1016\/j.clinthera.2023.12.002_bib0031","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkz087","article-title":"Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing","volume":"74","author":"Wicha","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0032","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cts.12734","article-title":"Prediction of metabolite-to-parent drug exposure: derivation and application of a mechanistic static model","volume":"13","author":"Callegari","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0033","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0034","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0035","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0036","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 3","key":"10.1016\/j.clinthera.2023.12.002_bib0037","doi-asserted-by":"crossref","first-page":"iii11","DOI":"10.1093\/jac\/dkz086","article-title":"Pharmacokinetics\/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae","volume":"74","author":"Wicha","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0038","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00322-11","article-title":"Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant","volume":"55","author":"Dugourd","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0039","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1128\/AAC.00778-13","article-title":"Effect of pulmonary surfactant on antimicrobial activity in vitro","volume":"57","author":"Schwameis","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"10.1016\/j.clinthera.2023.12.002_bib0040","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/jac\/dkz088","article-title":"Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using phase 1 data and population pharmacokinetics methods","volume":"74","author":"Zhang","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 3","key":"10.1016\/j.clinthera.2023.12.002_bib0041","doi-asserted-by":"crossref","first-page":"iii35","DOI":"10.1093\/jac\/dkz089","article-title":"Pharmacokinetic-pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia","volume":"74","author":"Bhavnani","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0042","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/jac\/dkv442","article-title":"Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid","volume":"71","author":"Zeitlinger","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237659","article-title":"Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model","volume":"16","author":"Hafner","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0044","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a027110","article-title":"Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance","volume":"7","author":"Paukner","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00619-21","article-title":"MIC Values of iclaprim and lefamulin against Mycobacterium abscessus complex","volume":"65","author":"Chew","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0046","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(13)60632-7","article-title":"Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study","volume":"381","author":"Bryant","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0047","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcf.2014.05.008","article-title":"Increasing nontuberculous mycobacteria infection in cystic fibrosis","volume":"14","author":"Bar-On","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0048","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/antibiotics10111370","article-title":"Determination of in vitro antimicrobial susceptibility for lefamulin (pleuromutilin) for Ureaplasma spp. and Mycoplasma hominis","volume":"10","author":"Spiller-Boulter","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0049","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1093\/jac\/dkac293","article-title":"Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark","volume":"77","author":"Day","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40262-020-00970-3","article-title":"Antibiotics in adult cystic fibrosis patients: a review of population pharmacokinetic analyses","volume":"60","author":"El Hassani","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0051","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/phar.2523","article-title":"Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis","volume":"41","author":"Wicha","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0052","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/phar.2522","article-title":"Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function","volume":"41","author":"Wicha","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"suppl 3","key":"10.1016\/j.clinthera.2023.12.002_bib0053","doi-asserted-by":"crossref","first-page":"iii5","DOI":"10.1093\/jac\/dkz085","article-title":"In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model","volume":"74","author":"Wicha","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0054","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/bcp.13324","article-title":"The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers","volume":"83","author":"Liddy","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0055","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/ppul.23971","article-title":"Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer","volume":"53","author":"Guimbellot","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0056","series-title":"Presented at: CHEST 2022 Annual Meeting; October 16-19","article-title":"Physiologically-based pharmacokinetic (PBPK) modeling of the combination of ivacaftor and lefamulin in cystic fibrosis patients","author":"Wicha","year":"2022"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0057","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2023.12.002_bib0058","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12890-017-0503-6","article-title":"Antibiotic duration and changes in FEV(1) are not associated with time until next exacerbation in adult cystic fibrosis: a single center study","volume":"17","author":"Espel","year":"2017","journal-title":"BMC Pulm Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:52Z","timestamp":1758963652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823004757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0149291823004757"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}